July 15, 2025

Figure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

MAIN FINDING: The first-in-class cdk4/6 inhibitor, PF-06873600, shows promising results when combined with endocrine therapy.
KEY EVIDENCE: The recommended dose for expansion (RDE) was determined to be 25 mg twice daily based on patient responses.
APPROACH: The study involved patients with various types of breast cancer, including hormone receptor-positive and triple negative breast cancer.
SIGNIFICANCE: This research may lead to improved treatment strategies for patients with metastatic breast cancer, enhancing therapeutic options.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I/IIa trial assesses cdk4/6 inhibitor's impact on treatment outcomes in patients with metastatic breast cancer, suggesting potential new therapy options.

Cite This Study

Yap et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc6dc https://doi.org/10.1158/1078-0432.29568395

View Full Paper

Ask AI

Bookmark

Implication

Phase I/IIa trial assesses cdk4/6 inhibitor's impact on treatment outcomes in patients with metastatic breast cancer, suggesting potential new therapy options.

Figure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Figure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider